In an interview with host Tracy Weslosky from InvestorNews, Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO Greg Fenton began their discussion on the substantial improvement in the aptamer platform’s binding affinity and yield as announced in their November 15th, 2023, release. Greg explains how the new platform may reduce the rapid clearance from the body, the researchers have increased the aptamer platform production to a 95% yield, which substantially reduces costs and positions them as potential replacements for monoclonal antibodies, offering efficiency and cost benefits.

Fenton highlights the rapid production capability of aptamers, taking only 6-8 weeks compared to longer durations for vaccines. Aptamers, composed of DNA sequences, are deemed safe and can be synthesized quickly for specific targets. This speed and cost-effectiveness give aptamers a competitive edge in the market, especially against antibody therapies.

He also discusses Zentek’s collaboration with McMaster University in medical research, noting that the aptamer platform is still in early stages but shows great potential. He emphasizes the importance of safety, dosing ranges, and further research to establish the platform’s market value.

Additionally, Zentek’s recent developments include ZenGUARD™ enhanced air filters, which offer significant cost savings in healthcare and energy efficiency. The filters reduce absenteeism and energy costs by requiring fewer air exchanges, representing economic benefits for building owners, businesses, and public healthcare systems.

Fenton also remarks on Zentek’s efficient use of funds, highlighting that their current stage of development would typically cost hundreds of millions of dollars, but they achieved it with a fraction of that amount. This efficiency is attributed to their partnership with McMaster University.

Finally, the addition of John Snisarenko, a former pharma industry executive, to Zentek’s board is seen as a strategic move to enhance the company’s outreach and partnership engagement in the pharmaceutical industry. His extensive pharmaceutical experience and connections are expected to be valuable for Zentek’s future development and commercialization strategy.

The news release from November 15, 2023, corroborates these developments, noting the substantial improvement in the aptamer platform’s binding affinity and yield. The release also highlights the potential for Zentek’s aptamers in precision therapy, competing with monoclonal antibodies, and the significant cost and timeline advantages inherent to their platform technology. Zentek’s CEO comments on the potential of the aptamer platform across various therapeutic areas and the company’s shift towards commercialization and partnership strategies. To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company’s commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek has a global exclusive license to the Aptamer-based platform technology developed by McMaster University which is being jointly developed Zentek and McMaster for both the diagnostic and therapeutic markets.

To learn more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

In a recent InvestorIntel interview, Peter Clausi speaks with Dr. Francis Dube, Executive Chairman, and Greg Fenton, CEO and Director of ZEN Graphene Solutions Ltd. (TSXV: ZEN), about ZEN Graphene’s potential graphene-based antibiotic, antiviral and antifungal compound which could be a medical breakthrough in the treatment of numerous human-contracted pathogens including COVID-19.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg went on to say, “We unfortunately had to shut down most of our research and development due to COVID-19.” He continued, “Fortunate for us, we had just opened up our own research lab in Guelph. We joined together with our research partners and tested to see if there was anything we could do to help beat this virus.”

Dr. Dube told InvestorIntel that ZEN Graphene has already filed patent for a graphene-based virucidal ink to be used in masks, PPE and the HVAC (Heating, ventilation, and air conditioning) sector. He added that the company is now exploring graphene’s use in the fight against the current global pandemic.

On December 22, 2020, ZEN Graphene Solutions announced that it had developed a potential graphene-based antibiotic, antiviral and antifungal compound. Commenting on this news release Greg said, “The versatility of this product is way beyond anything even we could have imagined. Not only the range of pathogens that it is effective against, but how it can be deployed and utilized. It went from us simply talking about bringing our product into coating, to us talking about actually bringing it into the body.”

To watch the full interview, click here

About ZEN Graphene Solutions Ltd.
ZEN is a graphene technology solutions company with a focus on the development of graphene based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a potential competitive advantage in the graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN’s Albany PureTM Graphite is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods. ZEN is focused on commercializing a patent pending graphene-based coating with 99% viricidal activity against

To learn more about ZEN Graphene Solutions Ltd., click here

ZEN Graphene Disclaimer: The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. The company must receive Health Canada or FDA approvals for any of the products or solutions discussed.

InvestorIntel Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.